# A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

> **NCT06508320** · PHASE2 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 932 (actual)

## Conditions studied

- Influenza
- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** mRNA-1083

## Key facts

- **NCT ID:** NCT06508320
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-15
- **Primary completion:** 2025-09-25
- **Final completion:** 2025-09-25
- **Target enrollment:** 932 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508320, "A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06508320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*